Given that the MAPK and PI3K/AKT/mTOR pathways are often dysregulated and interconnected in melanoma, and considering the role of the Warburg effect in influencing therapy response, the authors evaluated the impact of these treatments on the proliferation and survival of melanoma cells with different genetic profiles, suggesting that the combination of MAPK pathway inhibitors with mTOR pathway inhibitors and/or DCA should be considered as therapeutic options to treat melanoma patients, as the combinations potentiated the effects of each drug individually [162]. Here, AKT1 is linked to melanoma.